Hagens Berman & ImmunityBio
3 shared events · Importance 3 · Last updated May 27, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Hagens Berman: Hagens Berman is investigating claims that ImmunityBio violated federal securities laws and is urging investors with significant losses to join their class action lawsuit.
ImmunityBio: ImmunityBio is the defendant in multiple securities class action lawsuits due to alleged misleading statements about its drug Anktiva, which caused its stock price to fall significantly. The company faces investigations and potential financial penalties.
Apr 02, 2026 · 132 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Hagens Berman and ImmunityBio interact across events, view sentiment trends, and discover connected entities.
Open Dashboard